Holen Sie sich die Stockscreener-App
95.34
6.73%
5.62
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Citizens reiterates Rhythm Pharmaceuticals stock rating on bivamelagon data By Investing.com - Investing.com Canada
How This Biotech Is Taking On Genetic Obesity — And Winning - Investor's Business Daily
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials - TipRanks
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 - The Manila Times
Rhythm Pharmaceuticals (RYTM) reports strong MC4R obesity data across PWS, HO and BBS at ENDO 2026 - Stock Titan
Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists - TradingView
Rhythm trial finds up to 38% BMI drop in complex rare obesity cases - Stock Titan
Why Is Rhythm Pharma Stock Jumping Today? - Benzinga
Stifel reiterates Rhythm Pharmaceuticals stock rating on PWS data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Promising Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Rhythm Pharmaceuticals (RYTM) Announces Positive Phase 2 Trial R - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Rhythm Pharmaceuticals reports phase 2 PWS trial results By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals reports phase 2 PWS trial results - Investing.com
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 - The Manila Times
Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws - TradingView
Experimental PWS drug cuts body fat and hunger in small six-month trial - Stock Titan
Rhythm Pharmaceuticals Reports Positive Phase 2 Results for PWS Treatment - Intellectia AI
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase - GlobeNewswire
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
RYTM Technical Analysis & Stock Price Forecast - Intellectia AI
RYTM: ENDO to feature key Praloretel and RM-718 data as HO launch gains momentum in rare disease space - TradingView
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 59.95% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Long term debt to total assets ratio of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
EBITDA per share of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis Algorithm - Yahoo Finance
Book value per share of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Quick ratio of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
EBIT per share of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Rhythm Pharmaceuticals, Inc. Balance Sheet – XETR:1RV - TradingView
Rhythm Pharmaceuticals, Inc. Revenue Breakdown – XETR:1RV - TradingView
(RYTM) Risk Channels and Responsive Allocation - Stock Traders Daily
Rhythm Pharmaceuticals stock rating reaffirmed by Citizens - Investing.com Canada
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine - Seeking Alpha
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Eastern Progress
PTC Therapeutics Drops 6.3% Amid Sector-Wide Selling - AlphaStreet
Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 56% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
RYTM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals - Kavout
Rhythm Pharmaceuticals to Present Seven Abstracts at ENDO 2026, Highlighting Advances in Treatment for Rare Neuroendocrine Diseases - Quiver Quantitative
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 - GlobeNewswire
Inside Rhythm’s seven ENDO 2026 talks on hypothalamic obesity, PWS, BBS - Stock Titan
Breakeven On The Horizon For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Moomoo
Why Rhythm Pharmaceuticals stock triumphed on Tuesday - MSN
Rhythm Pharmaceuticals Announces Publication of New - GlobeNewswire
New Bardet-Biedl diagnostic guide tackles years-long diagnosis delays - Stock Titan
(RYTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rhythm Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 57% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock - Investing.com India
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) officer sells 4,643 shares after exercising options - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM): Exploring a 52.67% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM) - Stock Titan
Liquidity Mapping Around (RYTM) Price Events - Stock Traders Daily
Rhythm Pharmaceuticals, Inc.Common Stock (NQ: RYTM - FinancialContent
1.79%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):